Repository logo
 
Publication

Effects of CYP2C19 genetic polymorphism on the steady-state concentration of citalopram in patients with major depressive disorder

2021-02-19Journal article Restricted access
Simple item page
dc.contributor.authorZastrozhin, M. S.
dc.contributor.authorSkryabin, V. Yu
dc.contributor.authorPetukhov, A. E.
dc.contributor.authorTorrado, Marco
dc.contributor.authorPankratenko, E. P.
dc.contributor.authorZastrozhina, A. K.
dc.contributor.authorGrishina, E. A.
dc.contributor.authorRyzhikova, K. A.
dc.contributor.authorShipitsyn, V. V.
dc.contributor.authorBryun, E. A.
dc.contributor.authorSychev, D. A.
dc.date.accessioned2021-02-25T17:44:00Z
dc.date.available2021-02-25T17:44:00Z
dc.date.issued2021-02-19
dc.descriptionCopyright © 2021, The Author(s), under exclusive licence to Springer Nature Limited part of Springer Naturept_PT
dc.description.abstractCitalopram is commonly prescribed to patients suffering from major depressive disorder. Some of them do not respond adequately to therapy with citalopram, while many of them experience type A adverse drug reactions. Current research revealed that CYP2C19 isoenzyme is involved in the biotransformation of citalopram. The objective of our study was to investigate the impact of 681G>A polymorphism of the CYP2C19 gene on the efficacy, safety and the concentration/dose indicator of citalopram. Our study enrolled 130 patients with major depressive disorder and comorbid alcohol use disorder (average age-38.7 ± 14.1 years). Therapy regimen included citalopram in an average daily dose of 31.1 ± 14.4 mg per week. Therapy efficacy and safety were evaluated using the international psychometric scales. For genotyping, we performed the real-time polymerase chain reaction. Our findings revealed the statistically significant results in terms of the treatment efficacy evaluation (HAMD scores at the end of the treatment course): (GG) 8.0 [8.0; 9.0] and (GA) 10.0 [9.0; 11.0], p < 0.001. In the safety profile (the UKU scores), the statistical significance was also obtained: (GG) 3.0 [3.0; 4.0] and (GA) 5.0 [4.0; 5.0], p < 0.001. We revealed a statistical significance for concentration/dose indicator of citalopram in patients with different genotypes: (GG) 2.543 [1.659; 4.239] and (GA) 4.196 [2.643; 5.753], p < 0.001). The effect of CYP2C19 genetic polymorphism on the efficacy and safety profiles of citalopram was demonstrated in a group of 130 patients with major depressive disorder.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationPharmacogenomics J. 2021 Feb 19.pt_PT
dc.identifier.doi10.1038/s41397-021-00219-7pt_PT
dc.identifier.eissn1473-1150
dc.identifier.issn1470-269X
dc.identifier.urihttp://hdl.handle.net/10451/46531
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherSpringer Naturept_PT
dc.relation.publisherversionhttps://www.nature.com/tpj/pt_PT
dc.titleEffects of CYP2C19 genetic polymorphism on the steady-state concentration of citalopram in patients with major depressive disorderpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.titleThe Pharmacogenomics Journalpt_PT
person.familyNameTorrado
person.givenNameMarco
person.identifier.ciencia-id8819-FC01-6618
person.identifier.orcid0000-0002-4091-745X
rcaap.rightsrestrictedAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationad82e95f-8586-4302-83c8-9028e9d969a6
relation.isAuthorOfPublication.latestForDiscoveryad82e95f-8586-4302-83c8-9028e9d969a6

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
CYP2C19.pdf
Size:
387.37 KB
Format:
Adobe Portable Document Format
Download

Collections

FM-ISAMB-Artigos em Revistas Internacionais